Trenzyme recently developed the Lonza NucleofectionPLUS technology enabling cryostorage of transfection-competent mammalian cells. The NucleofectionPLUS technology was licensed to Lonza in November 2011. It will be available from Lonza as NucleofectionPLUS supplement for every Nucleofection kit available. In addition, the technology will be used by Lonza in collaboration with Trenzyme not only as kit supplement but as well as a service platform to provide life science researchers with high quality ready-to-transfect cells.